Oncolytic poliovirus for human tumors
US10398743B2 · kind B2 · utility
2Cited by
5References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 9, 2017 |
| Grant date | Sep 3, 2019 |
| Priority date | — |
| Expiry date | Feb 9, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.